Preul M C, Leblanc R, Caramanos Z, Kasrai R, Narayanan S, Arnold D L
Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, Quebec, Canada.
Can J Neurol Sci. 1998 Feb;25(1):13-22. doi: 10.1017/s0317167100033436.
It is often difficult to differentiate a recurrent glioma from the effects of post-operative radiotherapy by means of conventional neurodiagnostic imaging. Proton magnetic resonance spectroscopic imaging (1H-MRSI), that allows in vivo measurements of the concentration of brain metabolites such as choline-containing phospholipids (Cho), may provide in vivo biochemical information helpful in distinguishing areas of tumor recurrence from areas of radiation effect.
Two patients who had undergone resection and post-operative radiotherapy for a cerebral glioma became newly symptomatic. Computed tomographic (CT) and magnetic resonance imaging (MRI) performed after the intravenous infusion of contrast material, and in one case, [18F]fluorodeoxyglucose positron emission tomography (PET), could not differentiate between the possibilities of recurrent glioma and radiation effect. The patients underwent 1H-MRSI prior to reoperation and the 1H-MRSI results were compared to histological findings originating from the same locations.
A high Cho signal measured by 1H-MRSI was seen in areas of histologically-proven dense tumor recurrence, while low Cho signal was present where radiation changes predominated.
The differentiation between the recurrence of a cerebral glioma and the effects of post-operative irradiation was achieved using 1H-MRSI in these two patients whose conventional neurodiagnostic imaging was equivocal for such a distinction. Where these two conditions are present, metabolite images from 1H-MRSI, such as that based on Cho, can be co-registered with other imaging modalities such as MRI and may also be integrated with functional MRI or functional PET within a multimodal imaging-guided surgical navigation system to assure maximal resection of recurrent tumor while minimizing the risk of added neurological damage.
通过传统的神经诊断成像手段,往往难以区分复发性胶质瘤与术后放疗的影响。质子磁共振波谱成像(1H-MRSI)能够在体内测量脑代谢物的浓度,如含胆碱磷脂(Cho),可为区分肿瘤复发区域和放疗影响区域提供有用的体内生化信息。
两名接受过脑胶质瘤切除及术后放疗的患者出现了新的症状。静脉注射造影剂后进行的计算机断层扫描(CT)和磁共振成像(MRI),以及在其中一例中进行的[18F]氟脱氧葡萄糖正电子发射断层扫描(PET),均无法区分复发性胶质瘤和放疗影响的可能性。患者在再次手术前接受了1H-MRSI检查,并将1H-MRSI结果与来自相同部位的组织学检查结果进行了比较。
在组织学证实的密集肿瘤复发区域,1H-MRSI测量到高Cho信号,而在以放疗改变为主的区域则出现低Cho信号。
在这两名传统神经诊断成像对此区分不明确的患者中,使用1H-MRSI实现了脑胶质瘤复发与术后放疗影响的区分。在存在这两种情况时,来自1H-MRSI的代谢物图像,如基于Cho的图像,可与MRI等其他成像模态进行配准,也可在多模态成像引导的手术导航系统中与功能MRI或功能PET整合,以确保在将新增神经损伤风险降至最低的同时,最大程度地切除复发性肿瘤。